1. Impact of SARS-CoV-2 Pandemic on Patients with Primary Immunodeficiency.
- Author
-
Delavari S, Abolhassani H, Abolnezhadian F, Babaha F, Iranparast S, Ahanchian H, Moazzen N, Nabavi M, Arshi S, Fallahpour M, Bemanian MH, Shokri S, Momen T, Sadeghi-Shabestari M, Molatefi R, Shirkani A, Vosughimotlagh A, Safarirad M, Sharifzadeh M, Pashangzadeh S, Salami F, Shirmast P, Rezaei A, Moeini Shad T, Mohraz M, Rezaei N, Hammarström L, Yazdani R, and Aghamohamamdi A
- Subjects
- COVID-19 diagnosis, COVID-19 virology, Child, Preschool, Clinical Decision-Making, Comorbidity, Disease Management, Female, Humans, Infant, Male, Mortality, Primary Immunodeficiency Diseases diagnosis, Public Health Surveillance, Severity of Illness Index, COVID-19 complications, COVID-19 epidemiology, Health Impact Assessment, Primary Immunodeficiency Diseases complications, Primary Immunodeficiency Diseases epidemiology, SARS-CoV-2
- Abstract
Although it is estimated that COVID-19 life-threatening conditions may be diagnosed in less than 1:1000 infected individuals below the age of 50, but the real impact of this pandemic on pediatric patients with different types of primary immunodeficiency (PID) is not elucidated. The current prospective study on a national registry of PID patients showed that with only 1.23 folds higher incidence of infections, these patients present a 10-folds higher mortality rate compared to population mainly in patients with combined immunodeficiency and immune dysregulation. Therefore, further management modalities against COVID-19 should be considered to improve the survival rate in these two PID entities using hematopoietic stem cell transplantation and immunomodulatory agents.
- Published
- 2021
- Full Text
- View/download PDF